Improving Patient Adherence and Quality of Life in Metastatic Bladder Cancer: Strategies for Managing Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors

A continuing medical education activity provided by NAMCP and AAMCN

Recent Therapeutic Advances in the Management of Metastatic Bladder Cancer: Managed Care Perspectives on Immunotherapy in the First Line Setting is a three-part webinar series

This is Part 3 of the series focusing on first line management of metastatic bladder cancer

This activity is an archive from the webinar held February 3, 2021

This activity is valid from March 1, 2021 – June 30, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Pfizer and EMD Serono

Description:
Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. According to the American Cancer Society, there will be 80,470 new cases of bladder cancer and 17,670 deaths in the United States in 2020. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer. In particular, immune checkpoint inhibitors have changed the treatment paradigm, as recent data has shown that immunotherapy great improves outcomes, especially with maintenance therapy in the first line setting.

This webinar series on the continued integration of current and emerging immunotherapy into the treatment paradigm, with a focus on the first line maintenance setting, will provide attendees with updated education on differences in pharmacology, efficacy, and safety of these agents and roles that managed care professionals can play to drive appropriate access to and use of immune checkpoint inhibitors in various settings in locally advanced or metastatic bladder cancer to optimize clinical and economic outcomes for patients.

Upon completion of this activity, participants will be able to:

  • Examine challenges to patient adherence, administration and quality of life in the management of metastatic bladder cancer

  • Discuss strategies to implement immune checkpoint inhibitors into the treatment paradigm, especially as it relates to patient adherence and quality of life

  • Review strategies to prevent, anticipate, and manage immune-related adverse events (irAEs) in patients with metastatic bladder cancer

  • Explore the role of first-line immunotherapy maintenance in the management of metastatic bladder cancer

     

Faculty: Peter H. O’Donnell, MD
Associate Professor
Department of Medicine
Genitourinary Oncology Program
The University of Chicago

Disclosure:

Dr. O’Donnell has served as a consultant for Atheneum, Astellas, Dedham Group, FirstWord Publ., Genentech, HealthAdvances, Janssen, Merck, Pfizer, Schlesinger Assoc., and SeaGen. He has recerived grants/research funding from Acerta Pharma, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Janssen, Merck, and SeaGen. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships to disclose.
Jacqueline Cole, RN, MS, CPHQ, CMCN has no financial relationships to disclose.
Jeremy Williams has no financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from Pfizer and EMD Serono

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue